Pharmaceutical Companies in Bahrain
A comprehensive guide to the pharmaceutical industry in Bahrain — the smallest GCC market but well-regulated, with a $0.3B market growing at 5.8%. Covering major pharma companies, NHRA regulatory framework, Vision 2030 healthcare pillar, market data, distribution channels, and strategic advantages including proximity to Saudi Arabia.
Last updated: February 2026 · Sources: NHRA, BioNixus MEA, company filings, BioNixus research
Cite this guide
BioNixus. "Pharmaceutical Companies in Bahrain: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-bahrain.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$0.3B
Pharmaceutical market value
5.8%
Year-over-year growth
1.6M
Population
$188
Pharma spending per capita
Bahrain Pharmaceutical Market Overview
Bahrain's pharmaceutical market is the smallest in the GCC but well-regulated, valued at approximately US$0.3 billion and growing at 5.8% year-over-year. With a population of 1.6 million and per-capita pharmaceutical spending of $188, Bahrain is a compact market where the National Health Regulatory Authority (NHRA) operates as a modern regulator aligned with regional standards.
Approximately 95% of pharmaceuticals are imported, with local manufacturers Bahrain Pharma and Gulf Biotech serving part of the generics segment. Proximity to Saudi Arabia via the King Fahd Causeway is a strategic advantage for companies using Bahrain as a logistics hub or re-export base for the larger GCC market.
Vision 2030 (Bahrain's Economic Vision 2030) includes a healthcare pillar supporting NHRA regulatory modernisation, growing insurance coverage, and digital health. For regional context, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Bahrain
The following table lists the major pharmaceutical companies operating in Bahrain — including local manufacturers, multinational offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| Bahrain Pharma | Bahrain |
| Gulf Biotech | Bahrain |
| Pfizer | USA |
| Novartis | Switzerland |
| Roche | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK (GlaxoSmithKline) | UK |
| MSD (Merck & Co.) | USA |
| Novo Nordisk | Denmark |
| Julphar | UAE |
| Hikma Pharmaceuticals | Jordan / UK |
| SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances) | Saudi Arabia |
| Bahrain Pharmacy | Bahrain |
| Al Jishi Pharmacy | Bahrain |
| National Medical Supplies | Bahrain |
List of Pharmaceutical Companies in Bahrain by Category
Bahrain pharmaceutical companies span local manufacturers, multinational corporation offices, regional suppliers, and key distributors.
Local Manufacturers
Bahrain has a small but growing local manufacturing base. Bahrain Pharma is the leading local manufacturer (generics); Gulf Biotech operates from Bahrain Investment Wharf in biotech and generics.
- ✓ Bahrain Pharma
- ✓ Gulf Biotech
Multinational Pharma Offices
Major global pharmaceutical companies maintain presence in Bahrain. MNCs dominate the innovator segment and use Bahrain as a base for GCC operations given proximity to Saudi Arabia.
- ✓ Pfizer
- ✓ Novartis
- ✓ Roche
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK (GlaxoSmithKline)
- ✓ MSD (Merck & Co.)
- ✓ Novo Nordisk
Regional Pharma Companies
Regional players from UAE, Jordan, and Saudi Arabia supply Bahrain with generics and injectables. Julphar has strong Bahrain exports; Hikma and SPIMACO supply the market.
- ✓ Julphar
- ✓ Hikma Pharmaceuticals
- ✓ SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances)
Distributors
Bahrain Pharmacy, Al Jishi Pharmacy, and National Medical Supplies are key distributors serving government and private channels.
- ✓ Bahrain Pharmacy
- ✓ Al Jishi Pharmacy
- ✓ National Medical Supplies
Pharma Companies in Bahrain: NHRA Regulatory Landscape
The National Health Regulatory Authority (NHRA) is Bahrain's pharmaceutical regulator, with a modern framework aligned with GCC and international standards.
Regulatory Authority
The National Health Regulatory Authority (NHRA) oversees pharmaceutical registration, quality control, pricing, pharmacovigilance, and import licensing. Pricing follows reference pricing (GCC basket).
Registration Timeline
8–14 months
Renewal Period
5 years
Pricing Model
Reference pricing (GCC basket)
Key Registration Requirements
- ✓CTD dossier via NHRA processes
- ✓GMP certificates from recognised authorities
- ✓Stability data for GCC climate conditions
- ✓Arabic labelling mandatory
- ✓Clinical trial and bioequivalence data (generics)
- ✓Certificate of Pharmaceutical Product (CPP)
- Local authorised representative typically required
Vision 2030 & NHRA Modernisation
Bahrain's Economic Vision 2030 includes a healthcare pillar supporting NHRA regulatory modernisation, growing health insurance, and digital health. The free zone and logistics hub status, plus proximity to Saudi Arabia, support market access. For full GCC registration details, see our GCC Pharmaceutical Market Access Guide.
Drug Distribution Channels in Bahrain
Bahrain's pharmaceutical distribution is government-dominant, with the private sector growing.
Government Channel (Dominant)
Government hospitals form the backbone of procurement. Key facilities include King Hamad Hospital, Salmaniya Medical Complex, and BDF Hospital (Bahrain Defence Force).
- ► King Hamad Hospital
- ► Salmaniya Medical Complex
- ► BDF Hospital
- ► Government tender procurement
Private Sector (Growing)
The private sector is growing with expanding insurance and healthcare investment. Major private hospitals include American Mission Hospital and Royal Bahrain Hospital.
- ► American Mission Hospital
- ► Royal Bahrain Hospital
- ► Growing insurance coverage
- ► Pharmacy chains and distributors
Bahrain Pharmaceutical Market Growth Drivers
Vision 2030, NHRA modernisation, and strategic location drive growth in Bahrain's pharmaceutical sector.
Vision 2030 Healthcare Pillar
Bahrain's Economic Vision 2030 includes healthcare as a key pillar, supporting regulatory modernisation, insurance expansion, and investment in health infrastructure and digital health.
NHRA Regulatory Modernisation
NHRA is evolving as a modern regulator aligned with GCC and international standards, offering more predictable registration timelines and reference pricing (GCC basket).
Growing Insurance
Expanding health insurance coverage is driving private-sector utilisation and creating reimbursement dynamics that support pharmaceutical uptake.
Free Zone & Logistics Hub
Bahrain's free zone and logistics hub status makes it an attractive base for pharmaceutical distribution and re-export across the GCC.
Proximity to Saudi Market
The King Fahd Causeway connects Bahrain to Saudi Arabia, enabling companies to use Bahrain as a strategic base for accessing the larger Saudi market.
Digital Health
Investment in digital health and healthcare digitisation under Vision 2030 supports efficiency and creates opportunities for pharma engagement.
How BioNixus Supports Pharma Companies in Bahrain
BioNixus is a leading healthcare market research company with expertise in the Bahrain and GCC pharmaceutical markets. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Quantitative and qualitative research with Bahrain and GCC physicians. Arabic-English bilingual capabilities across government and private hospitals.
Market Access & NHRA Strategy
NHRA registration strategy, GCC reference pricing analysis, reimbursement landscape, and payer research for Bahrain and regional access.
Competitive Intelligence
Monitoring of competitor launches, tender outcomes, formulary changes, and market share across therapeutic areas in Bahrain and the GCC.
Market Entry Strategy
Market assessment including NHRA pathway analysis, local partner and distributor identification, and go-to-market planning for Bahrain and GCC hub strategies.
Frequently Asked Questions
How many pharmaceutical companies operate in Bahrain?
Bahrain has approximately 16 notable pharmaceutical companies including local manufacturers (Bahrain Pharma, Gulf Biotech), multinational offices (Pfizer, Novartis, Roche, Sanofi, AstraZeneca, GSK, MSD, Novo Nordisk), regional players (Julphar, Hikma, SPIMACO), and distributors (Bahrain Pharmacy, Al Jishi Pharmacy, National Medical Supplies). The market is the smallest in the GCC at $0.3 billion but well-regulated under NHRA.
What is the size of Bahrain's pharmaceutical market?
Bahrain's pharmaceutical market is valued at approximately US$0.3 billion, with 5.8% year-over-year growth. Per-capita pharmaceutical spending is around $188. The market is import-dependent (~95%) but benefits from NHRA regulatory modernisation and proximity to the Saudi market via the King Fahd Causeway.
How do you register a pharmaceutical product with NHRA?
Drug registration with the National Health Regulatory Authority (NHRA) of Bahrain typically takes 8–14 months. Requirements include a Common Technical Document (CTD), GMP certificates, stability data for GCC climate, Arabic labelling, and a local authorised representative. Registration is renewed every 5 years. NHRA uses reference pricing based on the GCC basket.
How does Vision 2030 affect Bahrain's pharmaceutical sector?
Bahrain's Economic Vision 2030 includes a healthcare pillar that supports regulatory modernisation (NHRA), growing health insurance coverage, and investment in digital health. The free zone and logistics hub status, plus proximity to Saudi Arabia, make Bahrain an attractive base for GCC market access.
Why is proximity to Saudi Arabia important for Bahrain pharma?
Bahrain is connected to Saudi Arabia by the King Fahd Causeway, making it a strategic logistics and re-export hub for the larger Saudi market. Many regional and MNC companies use Bahrain as a base for GCC operations. This proximity supports distribution and market access across both markets.
Do I need a local partner to sell pharmaceuticals in Bahrain?
Foreign pharmaceutical companies typically need a local authorised representative to handle NHRA regulatory submissions, in-country logistics, and pharmacovigilance. Local distributors (e.g. Bahrain Pharmacy, Al Jishi Pharmacy, National Medical Supplies) play a key role in market access.
Data Sources & Methodology
This guide aggregates publicly available information from:
- BioNixus Middle East & Africa Pharmaceutical Market Report
- NHRA — National Health Regulatory Authority (Bahrain)
- Bahrain Economic Vision 2030 documentation
- Company and distributor sources
- BioNixus proprietary research (Bahrain & GCC, 2024–2025)
For customised market intelligence on Bahrain, contact our team.
Need Market Intelligence on Bahrain?
BioNixus delivers custom pharmaceutical market research across Bahrain and the GCC — physician surveys, competitive intelligence, market access strategy, and KOL mapping.